Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
The Journal of Trauma and Acute Care Surgery|July 4, 2020
Early comprehensive testing for COVID-19 is essential to protect trauma centersParker Hu, Jan O Jansen, Rindi Uhlich, et al.
Gynecologic Oncology|May 2, 2015
Polymerase ε (POLE) ultra-mutated tumors induce robust tumor-specific CD4+ T cell responses in endometrial cancer patientsStefania Bellone, Floriana Centritto, Jonathan Black, et al.
American Journal of Obstetrics and Gynecology|August 15, 2015
Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitroStefania Bellone, Jonathan Black, Diana P English, et al.
Reproductive Sciences (Thousand Oaks, Calif.)|May 31, 2018
Adjuvant Hormonal Therapy for Low-Grade Endometrial Stromal SarcomaUma Deshmukh, Jonathan Black, Javier Perez-Irizarry, et al.
Journal of Experimental & Clinical Cancer Research : CR|October 18, 2015
Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitroFrancesca Ferrari, Stefania Bellone, Jonathan Black, et al.
Gynecologic and Obstetric Investigation|January 3, 2019
Ten-Year Comparison Study of Type 1 and 2 Endometrial Cancers: Risk Factors and OutcomesJacqueline Feinberg, Benjamin Albright, Jonathan Black, et al.
Molecular Cancer Therapeutics|September 4, 2015
Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In VivoSalvatore Lopez, Emiliano Cocco, Jonathan Black, et al.
Gynecologic Oncology|August 12, 2015
Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivoCarlton L Schwab, Diana P English, Jonathan Black, et al.
Journal of Cancer Research and Clinical Oncology|September 27, 2018
Impact of carboplatin hypersensitivity and desensitization on patients with recurrent ovarian cancerGary Altwerger, Esther B Florsheim, Gulden Menderes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 7, 2017
SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu ExpressionGulden Menderes, Elena Bonazzoli, Stefania Bellone, et al.
Pageof 5